Compounded Medication – Prescription Only

This product is a compounded injectable formulation containing tesamorelin acetate and is dispensed only pursuant to a valid prescription issued by a licensed healthcare provider. Tesamorelin acetate is a synthetic peptide analog modeled on growth hormone–releasing hormone (GHRH). In compounding practice, tesamorelin formulations may be prescribed when a provider determines that individualized formulation, concentration, vial quantity, or dosing considerations are clinically appropriate for a specific patient. This product is not available for self-selection and may only be dispensed following provider authorization.

Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). The FDA does not evaluate compounded formulations for safety, effectiveness, or manufacturing quality. Compounding is performed by a state-licensed pharmacy pursuant to a patient-specific prescription. This page provides general, non-therapeutic information for educational and compliance purposes only. It does not describe intended use, therapeutic benefit, endocrine effects, growth hormone activity, body composition changes, metabolic outcomes, or expected clinical results.

General Scientific Information (Non-Therapeutic)

Tesamorelin has been examined in scientific and laboratory environments for its amino-acid structure and its classification as a synthetic peptide analog of GHRH. Research descriptions focus on molecular structure and biochemical interaction with pituitary signaling pathways under controlled conditions. This information is provided solely for general scientific context. No claims are made regarding safety, effectiveness, hormone secretion, metabolic effects, disease modification, or suitability for any particular condition.

Formulation Considerations

Tesamorelin is commonly supplied as a lyophilized powder for reconstitution prior to administration. Differences in vial count, packaging (single vial versus multiple vials), or labeled strength reflect formulation and dispensing parameters and do not imply differences in clinical effect, potency, or therapeutic outcome. All formulation decisions are determined by the prescribing healthcare provider and compounding pharmacy.

Contraindications

Tesamorelin should not be used in individuals who have a known hypersensitivity or allergy to tesamorelin or any component of the compounded formulation; have active malignancy involving the pituitary or hypothalamic region; have experienced prior adverse reactions to peptide-based injections; or have other conditions in which peptide hormone–related therapy is contraindicated as determined by the prescribing healthcare provider. Use in pregnant or breastfeeding individuals should occur only if a licensed healthcare provider determines that potential risks and benefits have been carefully evaluated.

Warnings and Precautions

Peptide-based injectable formulations may be associated with local or systemic reactions. Injectable administration should be performed only as prescribed and supervised by a licensed healthcare provider. Patients should inform their healthcare provider of all medical conditions, medications, and supplements prior to use. This product should not be used outside provider-directed protocols.

Potential Side Effects

Reported side effects associated with injectable peptide formulations may include injection site reactions such as redness, swelling, irritation, or discomfort; headache; dizziness; flushing; nausea; fatigue; or transient systemic symptoms. Serious adverse reactions are uncommon but may occur. Patients should seek medical attention if they experience signs of a severe allergic reaction or unexpected systemic symptoms.